K4 Elite
K4 Elite
Ecnoglutide (XW003) is a long-acting GLP-1 receptor analogue engineered for signalling bias toward the cAMP pathway, evaluated in a completed programme of randomised phase 3 trials in type 2 diabetes and in overweight or obesity.
Ecnoglutide, development code XW003, is a synthetic glucagon-like peptide-1 (GLP-1) analogue developed by Sciwind Biosciences. It is described in the literature as a cAMP-signalling-biased GLP-1 receptor agonist, meaning it was engineered to preferentially engage the Gs/cAMP arm of receptor signalling relative to beta-arrestin recruitment.
Unlike most peptides in this library, ecnoglutide has advanced through a full randomised, double-blind phase 3 programme. Published trials include EECOH-1 (monotherapy versus placebo in type 2 diabetes), EECOH-2 (a 52-week open-label non-inferiority comparison against dulaglutide on a metformin background), and the SLIMMER trial in adults with overweight or obesity without diabetes.
This entry summarises those published trial reports and the receptor-pharmacology literature. It is reference material for research use only and contains no dosing guidance of any kind.
Ecnoglutide binds the GLP-1 receptor, a class B GPCR expressed on pancreatic beta cells, in the gastrointestinal tract and at several central nervous system sites. Canonical GLP-1 receptor activation raises intracellular cAMP through Gs coupling, which in beta cells potentiates glucose-dependent insulin secretion, and also recruits beta-arrestin, which drives receptor internalisation and desensitisation.
The design rationale described for ecnoglutide is signalling bias: preferential cAMP-pathway activation with comparatively reduced beta-arrestin recruitment. The published hypothesis is that reduced arrestin-mediated internalisation preserves receptor availability at the cell surface. Structural modification also confers a long circulating half-life supporting once-weekly administration in the trial programme.
SLIMMER (phase 3, overweight or obesity). Population/model: 664 randomised adults aged 18 to 75 with overweight or obesity and without diabetes, defined by BMI thresholds with or without weight-related comorbidity. Design: multicentre, randomised, double-blind, placebo-controlled, three active arms plus volume-matched placebo, 40 weeks. Measures: co-primary endpoints were percentage change in bodyweight and the proportion of participants achieving at least a 5 percent reduction in bodyweight at week 40. Outcome as reported by the investigators: greater and sustained bodyweight reduction in the active arms versus placebo, with a safety profile the authors described as favourable [3][5].
EECOH-1 (phase 3, type 2 diabetes). Population/model: adults with type 2 diabetes. Design: multicentre, randomised, double-blind, placebo-controlled monotherapy trial. Measure: glycaemic control endpoints. Outcome as reported: superiority over placebo on the primary glycaemic endpoint [1].
EECOH-2 (phase 3, active comparator). Population/model: adults with type 2 diabetes and elevated glucose concentrations on metformin monotherapy. Design: 52-week, multicentre, open-label, randomised non-inferiority trial against dulaglutide. Measure: change in glycaemic control at 52 weeks. Outcome as reported: non-inferiority criteria met versus the active comparator [2].
Receptor pharmacology characterisation. Model: GLP-1 receptor cell-based signalling assays. Measure: cAMP accumulation versus beta-arrestin recruitment. Reported outcome: a bias profile favouring the cAMP arm, which is the basis for the compound being described as a biased agonist in the trial literature [1][4].
Combinations examined in the research literature. Descriptive only — not a recommendation to combine compounds.